<DOC>
	<DOCNO>NCT03037385</DOCNO>
	<brief_summary>This Phase 1 , open-label , first-in-human study design evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , preliminary antineoplastic activity BLU-667 administer orally patient NSCLC , thyroid cancer solid tumor .</brief_summary>
	<brief_title>Phase 1 Study BLU-667 Patients With Thyroid Cancer , Non-Small Cell Lung Cancer , Other Advanced Solid Tumors</brief_title>
	<detailed_description>The study consist 2 part , dose-escalation part ( Part 1 ) expansion part ( Part 2 ) . Both part enroll patient advanced NSCLC , advance thyroid cancer advance solid tumor progress follow standard systemic therapy , adequately respond standard systemic therapy , patient intolerant declined standard therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>Key Diagnosis dose escalation ( Part 1 ) Pathologically document , definitively diagnose nonresectable advanced solid tumor . All patient treat dos &gt; 120 mg per day must medullary thyroid cancer ( MTC ) , RETaltered solid tumor per local assessment tumor tissue and/or blood . Diagnosis dose expansion ( Part 2 ) All patient Groups 1 , 2 4 must RETaltered ( exclude synonymous nonsense mutation ) solid tumor , determine local test tumor circulate tumor nucleic acid blood ; detail . Group 1 patient must pathologically document , definitively diagnose locally advanced metastatic NSCLC RET rearrangement previously treat tyrosine kinase inhibitor ( TKI ) inhibit RET , cabozantinib , vandetanib , ponatinib , sorafenib alectinib . Group 2 patient must pathologically document , definitively diagnose locally advanced metastatic NSCLC RET rearrangement previously treat TKI inhibits RET . Group 3 patient must pathologically document , definitively diagnose advanced MTC progress within 14 month prior Screening Visit . Group 4 patient must pathologically document , definitively diagnose advanced solid tumor RET alteration , NSCLC MTC . Patient must nonresectable disease progress follow standard therapy adequately respond standard therapy , patient must intolerant decline available standard therapy , must accept standard therapy disease . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 . Key Patient NSCLC targetable mutation EGFR , ALK , ROS1 . Patient follow within 14 day prior first dose study drug : 1 . Platelet count &lt; 75 × 10^9/L . 2 . Absolute neutrophil count &lt; 1.0 × 10^9/L . 3 . Hemoglobin &lt; 9.0 g/dL ( red blood cell transfusion erythropoietin may use reach least 9.0 g/dL , must administer least 2 week prior first dose study drug . 4 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3 × upper limit normal ( ULN ) hepatic metastasis present ; &gt; 5 × ULN hepatic metastasis present . 5 . Total bilirubin &gt; 1.5 × ULN ; &gt; 3 × ULN direct bilirubin &gt; 1.5 × ULN presence Gilbert 's disease . 6 . Estimated ( CockcroftGault formula ) measure creatinine clearance &lt; 40 mL/min . QT interval correct use Fridericia 's formula ( QTcF ) &gt; 470 msec history prolong QT syndrome Torsades de pointes , familial history prolong QT syndrome . Clinically significant , uncontrolled , cardiovascular disease . Central nervous system ( CNS ) metastases primary CNS tumor associate progressive neurological symptom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>medullary thyroid cancer</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>papillary thyroid cancer</keyword>
</DOC>